Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Inclusion Criteria:

Recurrent high-grade NMIBC Tis (with TaHG, or T1 also acceptable) within 24 months of the last treatment with BCG (with or without IFN)
Pathologic confirmation of stage, grade, and urothelial histology by the Department of Pathology at MSK
All visible papillary lesions macroscopically resected within 60 days of treatment initiation
Absence of urothelial carcinoma involving the upper urinary tract (documented by radiological imaging or ureteroscopy) within 12 months from the start of treatment
Receipt of restaging transurethral resection (TUR) for any tumor with invasion into the lamina propria (HGT1) as part of standard care
Age ≥18 years
Karnofsky performance status ≥60%
Informed consent

Exclusion Criteria:

Positive pregnancy test

Known contraindications to BCG

History of systemic hypersensitivity reaction or history of febrile systemic BCG reaction
Febrile illness or persistent gross hematuria
Active tuberculosis
Immunosuppression due to congenital or acquired immune deficiency, concurrent immune suppressive disease, systemic cancer therapy, or chronic immunosuppressive therapy other than topical or inhaled corticosteroids
History of or currently being treated for muscle-invasive (i.e., stage T2 or higher) or metastatic urothelial cell carcinoma
Evidence of concurrent extravesical (i.e., urethra, ureter, or renal pelvis) urothelial cell carcinoma

BCG-unresponsive NMIBC as defined by the FDA:

HGT1 within 3 months after an induction BCG course (received ≥5 of 6 doses)
Persistent or recurrent high-grade NMIBC (Tis, Ta, T1) within 6 months of ≥5 of 6 doses of induction BCG therapy and ≥2 of 3 doses of maintenance BCG therapy